SCHEMBL10248950

SCHEMBL10248950

Cc1ccc2c(c1)nc(-c1ccncc1S(C)(=O)=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
POLB P06746 1/20 0.43
AGPAT2 O15120 1/20 0.42
ATM Q13315 1/20 0.40
CA12 O43570 3/20 0.40
CA9 Q16790 3/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
CYP1A2 P05177 1/20 0.37
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36
CASP1 P29466 1/20 0.36
ACSS2 Q9NR19 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249057 0.88 SMN1; SMN2 (0.42) SMN1; SMN2POLBAGPAT2ATMCA12
SCHEMBL169041 0.85 PDE2A (0.50) SMN1; SMN2POLBAGPAT2ATMCA12
SCHEMBL10252540 0.82 CYP11B2 (0.49) RPS6KA5
SCHEMBL10249227 0.81 PDE10A (0.37) SMN1; SMN2POLBATMCA12CA9
SCHEMBL4399013 0.81 SMN1; SMN2 (0.49) SMN1; SMN2POLBAGPAT2ATMKDM4E
SCHEMBL10248880 0.80 SMN1; SMN2 (0.45) SMN1; SMN2POLBAGPAT2ATMKDM4E
SCHEMBL10249024 0.79 SMN1; SMN2 (0.47) SMN1; SMN2POLBAGPAT2ATMKDM4E
SCHEMBL10248939 0.79 AGPAT2 (0.50) SMN1; SMN2POLBAGPAT2ATMKDM4E
SCHEMBL10249177 0.79 SMN1; SMN2 (0.47) SMN1; SMN2POLBAGPAT2ATMCA12
SCHEMBL10248930 0.77 SMN1; SMN2 (0.45) SMN1; SMN2POLBAGPAT2ATMCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885AGPAT2 3286/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885AGPAT2 3286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.